Jesper Parnevik

EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co.

EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland.